- Home
- TAP vs NBIX Comparison
TAP vs NBIX Comparison
Compare TAP & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAP
- NBIX
- Stock Information
- Founded
- TAP 1873
- NBIX 1992
- Country
- TAP United States
- NBIX United States
- Employees
- TAP N/A
- NBIX N/A
- Industry
- TAP Beverages (Production/Distribution)
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TAP Consumer Staples
- NBIX Health Care
- Exchange
- TAP Nasdaq
- NBIX Nasdaq
- Market Cap
- TAP 12.6B
- NBIX 13.7B
- IPO Year
- TAP N/A
- NBIX 1996
- Fundamental
- Price
- TAP $55.24
- NBIX $143.26
- Analyst Decision
- TAP Hold
- NBIX Buy
- Analyst Count
- TAP 14
- NBIX 22
- Target Price
- TAP $61.79
- NBIX $164.81
- AVG Volume (30 Days)
- TAP 1.8M
- NBIX 1.0M
- Earning Date
- TAP 02-13-2025
- NBIX 02-05-2025
- Dividend Yield
- TAP 3.19%
- NBIX N/A
- EPS Growth
- TAP 275.92
- NBIX 97.40
- EPS
- TAP 4.42
- NBIX 3.73
- Revenue
- TAP $11,682,200,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- TAP $0.08
- NBIX $27.07
- Revenue Next Year
- TAP N/A
- NBIX $17.14
- P/E Ratio
- TAP $12.49
- NBIX $38.43
- Revenue Growth
- TAP 1.23
- NBIX 25.72
- 52 Week Low
- TAP $49.19
- NBIX $110.95
- 52 Week High
- TAP $69.18
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- TAP 41.58
- NBIX 66.20
- Support Level
- TAP $54.02
- NBIX $138.66
- Resistance Level
- TAP $55.11
- NBIX $144.24
- Average True Range (ATR)
- TAP 1.33
- NBIX 3.23
- MACD
- TAP -0.08
- NBIX 0.07
- Stochastic Oscillator
- TAP 50.53
- NBIX 82.29
About TAP Molson Coors Beverage Company Class B
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the us, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the us, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.